文献速递神经介入DSA

量化动脉内维拉帕米反应作为可逆性脑血管收缩综合征诊断工具

Quantifying Intra-Arterial Verapamil Response as a Diagnostic Tool for Reversible Cerebral Vasoconstriction Syndrome.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-09-17

前瞻性注册研究纳入26例非侵入性影像怀疑颅内动脉病并转诊行数字减影血管造影的患者,在节段性不规则血管区域行动脉内维拉帕米,量化管径变化。最终9例(34.6%)诊断为可逆性脑血管收缩综合征,所有该病患者均对维拉帕米有反应;最大管径变化比例≥32%诊断敏感度100%、特异度88.2%(AUC=0.951),优于RCVS-2评分≥5分(AUC=0.908,敏感度77.8%、特异度94.1%)。

要点

  • 最大管径变化比例≥32%诊断RCVS的敏感度100%、特异度88.2%,AUC=0.951。
  • 所有最终诊断RCVS的患者均对动脉内维拉帕米有反应。
  • RCVS-2评分≥5分AUC=0.908,敏感度77.8%、特异度94.1%。

关键影像表现/征象

  • 在节段性不规则血管区域行动脉内维拉帕米后测量管径变化,包括管径差(Caliberpost - Caliberpre)和管径变化比例([(Caliberpost - Caliberpre)/Caliberpre] × 100%)。

诊断标准与关键数值

  • 最大管径变化比例≥32%检测RCVS的敏感度100%、特异度88.2%,AUC=0.951。
  • RCVS-2评分≥5分诊断RCVS的AUC=0.908,敏感度77.8%、特异度94.1%。
  • RCVS患者与其他血管病患者的管径变化最大比例(P < .001)、平均比例(P = .002)、最大管径差(P = .004)和平均管径差(P = .001)差异有统计学意义。

临床应用与阅片要点

  • 对非侵入性影像怀疑颅内动脉病并转诊行数字减影血管造影的患者,可在节段性不规则血管区域行动脉内维拉帕米并量化管径变化,最大管径变化比例≥32%时诊断RCVS的敏感度100%、特异度88.2%。
  • RCVS-2评分≥5分诊断RCVS的AUC=0.908,敏感度77.8%、特异度94.1%,低于最大管径变化比例≥32%的AUC=0.951。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: There is mounting evidence supporting the benefit of intra-arterial administration of vasodilators in diagnosing reversible cerebral vasoconstriction syndrome. We prospectively quantified the degree of luminal diameter dilation after intra-arterial administration of verapamil and its accuracy in diagnosing reversible cerebral vasoconstriction syndrome.

MATERIALS AND METHODS: Patients suspected of having intracranial arteriopathy on noninvasive imaging and referred for digital subtraction angiography were enrolled in a prospective registry. Intra-arterial verapamil was administered in vascular territories with segmental irregularities. The caliber difference (Caliberpost - Caliberpre) and the proportion of caliber change ([(Caliberpost - Caliberpre)/Caliberpre] × 100%) were used to determine the response to verapamil. The diagnosis of reversible cerebral vasoconstriction syndrome was made on the basis of clinical and imaging features at a follow-up appointment, independent of the reversibility of verapamil. Receiver operating characteristic curve analysis was performed to determine the best threshold.

RESULTS: Twenty-six patients were included, and 9 (34.6%) were diagnosed with reversible cerebral vasoconstriction syndrome. A total of 213 vascular segments were assessed on diagnostic angiography. Every patient with a final diagnosis of reversible cerebral vasoconstriction syndrome responded to intra-arterial verapamil. The maximal proportion of change (P < .001), mean proportion of change (P = .002), maximal caliber difference (P = .004), and mean caliber difference (P = .001) were statistically different between patients with reversible cerebral vasoconstriction syndrome and other vasculopathies. A maximal proportion of change ≥32% showed a sensitivity of 100% and a specificity of 88.2% to detect reversible cerebral vasoconstriction syndrome (area under the curve = 0.951). The Reversible Cerebral Vasoconstriction Syndrome-2 score of ≥5 points achieved a lower area under the curve (0.908), with a sensitivity of 77.8% and a specificity of 94.1%.

CONCLUSIONS: Objective measurement of the change in the arterial calibers after intra-arterial verapamil is accurate in distinguishing reversible cerebral vasoconstriction syndrome from other vasculopathies. A proportion of change ≥32% has the best diagnostic performance.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Sequeiros JM, Roa JA, Sabotin RP, et al. Quantifying Intra-Arterial Verapamil Response as a Diagnostic Tool for Reversible Cerebral Vasoconstriction Syndrome. AJNR Am J Neuroradiol. 2020. PMID: 32943423. doi:10.3174/ajnr.A6772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。